Genmab
GMAB
213 hedge funds and large institutions have $1.59B invested in Genmab in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 71 increasing their positions, 82 reducing their positions, and 32 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $1.62B → $1.59B (-$35.9M)
9% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 32
1% less funds holding
Funds holding: 216 → 213 (-3)
2.89% less ownership
Funds ownership: 66.04% → 63.15% (-2.9%)
12% less call options, than puts
Call options by funds: $581K | Put options by funds: $661K
13% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$56.7M |
| 2 |
Two Sigma Investments
New York
|
+$5.38M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$4.49M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.48M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$4.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$38.3M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$24.7M |
| 3 |
Millennium Management
New York
|
-$11.9M |
| 4 |
Renaissance Technologies
New York
|
-$8.39M |
| 5 |
Goldman Sachs
New York
|
-$7.66M |
GMAB Hedge Fund Activity: Q2 2023 in Review
213 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q2 2023, worth a combined $1.59B — down 2.2% from $1.62B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of GMAB and 29 opened new positions — a net loss of 3 holders — while 82 trimmed existing stakes and 71 added.
The largest buyer was AllianceBernstein, adding an estimated $56.7M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $38.3M sold.
- 213 institutional investors held Genmab (GMAB) as of Q2 2023, down from 216 in Q1 2023.
- Funds reported $1.59B of Genmab stock for Q2 2023, down 2.2% quarter-over-quarter.
- 29 funds opened new Genmab positions in Q2 2023 and 32 closed out, a net change of -3 holders.
- The largest Genmab buyer in Q2 2023 was AllianceBernstein, an estimated $56.7M added.
- The largest Genmab seller in Q2 2023 was Arrowstreet Capital, an estimated $38.3M sold.
Based on aggregated 13F filings for Q2 2023.